Perucca E, Albrici A, Gatti G, Spalluto R, Visconti M, Crema A
Eur J Drug Metab Pharmacokinet. 1984 Jul-Sep;9(3):267-74. doi: 10.1007/BF03189650.
The kinetics of oxiracetam after single intravenous and oral doses (2000 mg) were investigated in four healthy volunteers. Following intravenous administration, the decline in serum levels showed a prolonged, rapid phase followed by a delayed terminal phase. Mean residence times ranged from 3.9 to 6.5 h. Volumes of distribution ranged from 0.9 to 1.81 X kg-1, whereas clearance values ranged from 100 to 119 ml X h-1 X kg-1 More than 90% of the intravenous dose was recovered unchanged in the urine within 48 h. Oral administration resulted in peak levels within 1-2 h; thereafter, the decline in serum levels showed a pattern similar to that observed after the intravenous dose--almost 50% of the oral dose was excreted in the urine within 6 h. The absolute availability of oral oxiracetam was 75 +/- 7%.
在4名健康志愿者中研究了单次静脉注射和口服（2000毫克）奥西拉坦后的动力学。静脉给药后，血清水平下降呈现出一个延长的快速阶段，随后是一个延迟的终末阶段。平均驻留时间为3.9至6.5小时。分布容积为0.9至1.81Xkg-1，清除率值为100至119mlXh-1Xkg-1。超过90%的静脉剂量在48小时内以原形在尿液中回收。口服给药后1-2小时内达到峰值水平；此后，血清水平下降呈现出与静脉给药后相似的模式——近50%的口服剂量在6小时内从尿液中排出。口服奥西拉坦的绝对生物利用度为75±7%。
